Status:
COMPLETED
Trachoma Amelioration in Northern Amhara (TANA)
Lead Sponsor:
University of California, San Francisco
Conditions:
Trachoma
Chlamydia
Eligibility:
All Genders
1+ years
Phase:
PHASE4
Brief Summary
The WHO has initiated a program to eliminate trachoma, blinding eye infection caused by Chlamydia trachomatis, in large part by mass distributions of oral azithromycin. The proposed study will determi...
Detailed Description
The proposed study is a group-randomized trial to determine the frequency and treatment target of community-wide mass antibiotic treatment to eliminate trachoma. We will also study the impact of commu...
Eligibility Criteria
Inclusion
- • All residents residing in the state-teams which are randomly selected for this study.
Exclusion
- Pregnant women
- Children under 6 months of age
- All those who are allergic to macrolides or azalides
- Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)
- Individuals in these three exclusion criteria will not be given the study antibiotic azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day, topically to both eyes, for six weeks. Note that the exclusion criteria refer to the exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and examinations.
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
33000 Patients enrolled
Trial Details
Trial ID
NCT00322972
Start Date
June 1 2006
End Date
May 1 2014
Last Update
September 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Carter Center, Ethiopia
Addis Ababa, Ethiopia